6.5 in Large Growth
U.S. News evaluated 469 Large Growth Funds. Our list highlights the top-rated funds for long-term investors based on the ratings of leading fund industry researchers.
| Scorecard | |
|---|---|
| Morningstar | 3 / 5 Stars |
| Lipper | 4 4 5 5 3 |
| Zacks Investment Research | 4 (Sell) |
| Standard & Poor's | 4 / 5 Stars |
| TheStreet.com | C+ (Hold) |
Fund Overview
With only about $300 million total assets under management, this fund is the smallest of the six funds managed by Primecap. A small asset base generally makes it easier for the fund to move in and out of positions. It also boasts a low turnover rate. As of the end of December 2009, the fund is invested in about 90 stocks. Almost a third of the fund’s total assets are in the healthcare sector in names like Eli Lilly, Roche and Amgen.
| Trailing Returns | Updated 03.31.2012 |
|---|---|
| Year to date | 8.7% |
| 1 Year | 5.5% |
| 3 Years (Annualized) | 21.4% |
| 5 Years (Annualized) | 3.4% |
| 10 Years (Annualized) |
Investment Strategy
The investment seeks to provide long-term capital appreciation. The fund invests mainly in stocks of U.S. companies, emphasizing those companies with financial results which the Advisor believes will evolve materially better than consensus expectations. It invests at least 80% of its assets in stocks and may invest in publicly-traded companies of any size and in foreign securities. The Advisor may sell a stock if its market price appears to have risen above its fundamental value, if other securities appear to be more favorably priced, or if the reasons for which the stock was purchased no longer hold true.
Fund Opinion
In the April 2010 edition The No-Load Fund Investor says, "PRIMECAP seeks companies whose financial results will exceed consensus expectations over a three to five year period, and/or whose asset values are not fully reflected in their stock prices."
2010-06-02
Performance
The fund has returned 5.49 percent over the past year, 21.39 percent over the past three years, and 3.37 percent over the past five years.
Hypothetical Growth of $10,000
Updated 03.31.2012
Holdings
Asset Allocation
| % Long | % Net | |
|---|---|---|
| Cash | 10.13 | 10.13 |
| Stocks | 76.12 | 76.12 |
| Bonds | 0.0 | 0.0 |
| Other | 0.0 | 0.0 |
| Foreign Bonds | 0.0 | 0.0 |
| Foreign Stocks | 13.75 | 13.75 |
| Convertible | 0.0 | 0.0 |
| Preferred | 0.0 | 0.0 |
Updated 12.31.2011
Top Holdings
Performance as of 03.31.2012
Portfolio as of 12.31.2011
| Ticker | YTD Return % | % Net Assets | |
|---|---|---|---|
| Dreyfus Treasury Pr Cash Mgmt Inv | --- | --- | 10.13 |
| Johnson & Johnson | JNJ | 1.83 | 4.42 |
| Amgen Inc | AMGN | 6.63 | 4.13 |
| Roche Holding AG | RHHVF | 8.29 | 4.01 |
| Texas Instruments, Inc. | TXN | 14.82 | 3.44 |
Fees
PrimeCap Odyssey Stock Fund has an expense ratio of 0.66 percent.
